Chiara Catania

Dr. Chiara Catania

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in ESMO Open
Verified
Journal Article
Open access
CCChiara Catania
Chiara Catania
SLS.V. Liu
S.V. Liu
MGM. Garassino
M. Garassino
ADA. Delmonte
A. Delmonte
VSV. Scotti
V. Scotti
TPT. De Pas
T. De Pas
Histological transformation to small-cell lung cancer (SCLC) is an under-recognized but clinically relevant mechanism of resistance in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). While platinum-based chemotherapy (CT) has emerged as standard treatment after small-cell transformation, optimal treatment strategies are not defined, particularly with regard to the role of immune checkpoint inhibitors (ICIs) or continuation of EGFR-tyrosine kinase inhibitors (TKIs). We conducted an international, retrospective, observational study on patients with EGFR-mutated NSCLC that transformed to SCLC, focusing on treatment and outcomes. Twenty-five patients across 11 centers were included. Twenty-four changed systemic treatment following SCLC transformation: CT (12 patients), CT plus EGFR-TKI (5 patients), CT plus ICI (6 patients), or CT plus ICI plus EGFR-TKI (1 patient). Median follow-up was 9 months (range 1-45 months). All patients experienced relapse with a median progression-free survival of 2 months [95% confidence interval (CI) 2-3 months] and 23 patients died, with a median overall survival (OS) of 9 months (95% CI 7-16 months). Median OS was comparable between patients treated with CT alone [9.5 months; 95% CI 5 months-not reached (NR)], CT plus EGFR-TKI (8 months; 95% CI 8 months-NR), and CT plus ICI (10 months; 95% CI 7 months-NR). Three patients survived >24 months from SCLC transformation; these patients were treated with CT alone (one patient), CT plus EGFR-TKI (one patient), and CT plus ICI and EGFR-TKI (one patient). OS was longer if SCLC transformation occurred >12 months from initial NSCLC diagnosis (19 patients) versus those with transformation within 12 months (6 patients): 31 versus 8 months (P < 0.001). The prognosis of patients with transformed SCLC remains poor, with only a minority achieving meaningful survival. Survival was similar in patients treated with CT alone or with the addition of ICI or EGFR-TKI. A time interval >12 months between NSCLC diagnosis and SCLC transformation was associated with longer survival and may reflect a different biology than early transformation.

24 August 2023 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CCChiara Catania
Chiara Catania
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
CSClaudia Sangalli
Claudia Sangalli
GPGaia Piperno
Gaia Piperno
MRMarco Russano
Marco Russano
ARAlessandro Russo
Alessandro Russo

20 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
NDNunzio Digiacomo
Nunzio Digiacomo
Tommaso De PasTommaso De Pas
Tommaso De Pas
GRGiovanna Rossi
Giovanna Rossi
PBPaola Bossi
Paola Bossi
ESErika Stucchi
Erika Stucchi
CCChiara Catania
Chiara Catania
Small-cell lung cancer (SCLC) transformation from EGFR mutant adenocarcinoma is a rare entity that is considered to be a new phenotype of SCLC. While transformation from adenocarcinoma (ADC) with EGFR exon 19 deletions and exon 21 L858R point mutations has been described, to our knowledge, no cases of transformation to SCLC from exon-18-mutated ADC have been reported. We reported a clinical case of a patient with exon-18-EGFR-transformed SCLC, and we performed a systematic review of the literature.

31 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FCFabio Conforti
Fabio Conforti
LPLaura Pala
Laura Pala
Tommaso De PasTommaso De Pas
Tommaso De Pas
EZEmma Zattarin
Emma Zattarin
CCChiara Catania
Chiara Catania
GVGiuseppe Viale
Giuseppe Viale
After decades of research, improving the efficacy of adjuvant endocrine therapy (ET) for early-stage breast cancer becomes increasingly difficult. Beyond technological breakthroughs and the availability of new classes of drugs, further improvement of adjuvant ET will require applying a rigorous research approach in poorly investigated areas. We critically discuss some key principles that should inform future research to improve ET efficacy, including identifying specific subgroups of patients who can benefit from escalating or de-escalating approaches, optimizing available and new treatment strategies for different clinical contexts, and dissecting the direct and indirect biological effects of therapeutic interventions. Four main issues regarding adjuvant ET were identified as relevant areas, where a better application of such principles can provide positive results in the near future: (i) tailoring the optimal duration of adjuvant ET, (ii) optimizing ovarian function suppression for premenopausal women, (iii) dissecting the biological effects of estrogen receptor manipulation, and (iv) refining the selection of patients to candidate for treatments escalation.

25 February 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
LPLaura Pala
Laura Pala
FMFederico Merlo
Federico Merlo
ISIsabella Sala
Isabella Sala
EPEleonora Pagan
Eleonora Pagan
COChiara Oriecuia
Chiara Oriecuia
FCFabio Conforti
Fabio Conforti
Background: The surrogacy of overall response rate (ORR) or progression-free survival (PFS) for overall survival (OS) at the trial-level in randomized clinical trials (RCTs) testing antibody-drugs conjugates (ADC) has never been investigated. Methods: RCTs testing ADCs in patients with advanced solid tumors and reporting data on OS and PFS and/or ORR were analyzed. The main objective was to assess the trial-level association between the surrogate endpoints (ORR or PFS) and the reference endpoint (OS), overall and in subgroups of trials defined by tumor type, number of previous lines of systemic treatments, and specific ADC features. Results: Twenty-five RCTs, for a total of 26 treatment comparisons and 11 729 patients, were included in the analysis. In 21 comparisons the ADC was administered as monotherapy, and in 16 was tested in patients with breast cancer. The association between the hazard ratio for OS and relative risk of ORR was moderate: the R2 from a model adjusted by tumor type was 0.47 (95% CI = 0.11 to 0.83). The association between the hazard ratios for OS and PFS was strong: the R2 from the adjusted model was 0.79 (95% CI = 0.66 to 0.92). Cross-validation analyses showed similar results. Consistent results were obtained across all the subgroups analyzed, with the notable exception of the subgroup of trials testing ADCs for breast cancer, where the association between OS and ORR appeared strong (R2 = 0.77; 95% CI = 0.51 to 0.90). Conclusions: In RCTs evaluating ADCs in advanced solid tumors, PFS serves as a robust surrogate endpoint for OS, offering greater reliability than ORR and adequately supporting accelerated approval of ADCs in future trials.

27 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Tommaso De PasTommaso De Pas
Tommaso De Pas
GGGiuseppe Giaccone
Giuseppe Giaccone
CCChiara Catania
Chiara Catania
FCFabio Conforti
Fabio Conforti
LPLaura Pala
Laura Pala
PDPierre-Yves Dietrich
Pierre-Yves Dietrich
The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in many solid tumors, particularly in Non-Small Cell Lung Cancer. Although data on the correlation between genetic alterations and response to immunotherapy are available in the majority of common cancers, data are lacking in the subset of patients with KIT-mutated Thymic Carcinoma (TC). As a consequence, although immunotherapy is a standard treatment for TC patients, the lack of this knowledge leads to uncertainty when proposing immunocheckpoint inhibitors in this subset of patients. Here we describe the first report of a patient with KIT-mutated TC who received the anti-PD1 agent pembrolizumab, which caused a sustained partial response. This case report of a sustained partial response achieved with pembrolizumab in a patient with KIT-mutated TC after progression to chemotherapy and imatinib may be supportive during clinical decision making for this extremely rare disease.